<SEC-DOCUMENT>0001104659-20-106112.txt : 20200917
<SEC-HEADER>0001104659-20-106112.hdr.sgml : 20200917
<ACCEPTANCE-DATETIME>20200917161602
ACCESSION NUMBER:		0001104659-20-106112
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200911
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200917
DATE AS OF CHANGE:		20200917

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PHIBRO ANIMAL HEALTH CORP
		CENTRAL INDEX KEY:			0001069899
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				131840497
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36410
		FILM NUMBER:		201181373

	BUSINESS ADDRESS:	
		STREET 1:		GLENPOINTE CENTRE EAST, 3RD FLOOR
		STREET 2:		300 FRANK W. BURR BLVD., SUITE 21
		CITY:			TEANECK
		STATE:			NJ
		ZIP:			07666
		BUSINESS PHONE:		201-329-7300

	MAIL ADDRESS:	
		STREET 1:		GLENPOINTE CENTRE EAST, 3RD FLOOR
		STREET 2:		300 FRANK W. BURR BLVD., SUITE 21
		CITY:			TEANECK
		STATE:			NJ
		ZIP:			07666

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PHILIPP BROTHERS CHEMICALS INC
		DATE OF NAME CHANGE:	19980908
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2030959d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;<B>UNITED STATES</B><BR>
<B>SECURITIES AND EXCHANGE COMMISSION</B><BR>
<B>WASHINGTON, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>__________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(D) OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of report (Date of earliest event reported):
September 17, 2020 (September 11, 2020)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Phibro Animal Health Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">___________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(EXACT NAME OF REGISTRANT AS SPECIFIED IN
CHARTER)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; width: 32%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Delaware</B></P></TD>
    <TD STYLE="padding-bottom: 1pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 32%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>01-36410</B></P></TD>
    <TD STYLE="padding-bottom: 1pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 32%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>13-1840497</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(State or other jurisdiction of incorporation)</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Commission File Number)</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(IRS Employer Identification No.)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Glenpointe Centre East, 3rd Floor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>300 Frank W. Burr Boulevard, Suite 21</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Teaneck, New Jersey 07666-6712</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">_______________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Address of Principal Executive Offices,
including Zip Code)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(201) 329-7300</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">__________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Registrant&rsquo;s telephone number,
including area code)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Not Applicable</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">__________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Former name or former address, if changed
since last report)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Securities registered pursuant to Section
12(b) of the Act:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 37%; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Title of each class</U></B></FONT></TD>
    <TD STYLE="width: 26%; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Trading Symbol(s)</U></B></FONT></TD>
    <TD STYLE="width: 37%; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Name of each exchange on which registered</U></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Class A Common Stock, $0.0001 par value per share</B></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PAHC</B></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASDAQ Stock Market</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if this
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Indicate by check mark whether the
registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &sect;230.405) or Rule 12b-2
of the Securities Exchange Act of 1934 (17 CFR &sect;240.12b-2).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Emerging growth company <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>ITEM
5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS
OF CERTAIN OFFICERS. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231F20">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
September 17, 2020, Phibro Animal Health Corporation (the &ldquo;Company&rdquo;) announced that on September 11, 2020, Richard
G. Johnson informed the Company that he will retire from his position as Chief Financial Officer of the Company effective November
15, 2020, subsequent to the Company&rsquo;s 2020 annual meeting and completion of the Company&rsquo;s earnings report for the quarter
ending September 30, 2020. Mr. Johnson will continue with the Company for a period of time in an advisory capacity to ensure a
smooth transition with his successor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231F20">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
September 17, 2020, the Company announced that on September 14, 2020, the Company entered into an offer letter with Damian Finio
(the &ldquo;Offer Letter&rdquo;). Pursuant to the Offer Letter, Mr. Finio will become employed by the Company on October 26, 2020,
and will succeed Mr. Johnson in the role of Chief Financial Officer of the Company effective November 15, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; color: #231F20">Since February 2018, Mr.
Finio, age 50, has served as Chief Financial Officer and Corporate Secretary of Teligent, Inc., a publicly traded global manufacturer
and distributor of topical pharmaceutical products in the United States and injectable pharmaceutical products in Canada. Until
July 2020, Mr. Finio also served as the Corporate Secretary of Teligent. Mr. Finio has over 29 years of financial management experience.
From November 2015 through January 2018, Mr. Finio served as Chief Financial Officer of Virtus Pharmaceuticals LLC, a specialty
pharmaceutical company covering a broad range of therapeutic areas. From August 2014 through November 2015, Mr. Finio was SVP Finance
of Heritage Pharmaceuticals Inc. (now known as Avet Pharmaceuticals Inc.), a marketer of generic pharmaceutical products. Earlier
in his career, Mr. Finio served as VP Finance of Daiichi Sankyo Pharma Development, CFO of West-Ward Pharmaceuticals (now known
as Hikma), and spent nearly 14 years in a variety of financial roles of increasing responsibility at AstraZeneca. He began his
career in public accounting at KPMG LLP. Mr. Finio has a Bachelor of Science in Accounting from The Pennsylvania State University
and a Masters in Business Administration from the University of Delaware, and is an (inactive) Certified Public Accountant and
(inactive) Certified Treasury Professional.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There are no family relationships between
Mr. Finio and any director, executive officer or person nominated or chosen by the Company to become a director or executive officer.
Additionally, there have been no transactions involving Mr. Finio that would require disclosure under Item 404(a) of Regulation
S-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Summary of Offer Letter to Mr. Finio</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; color: #231F20">Pursuant to the Offer Letter,
Mr. Finio will receive a base salary of $450,000, which is subject to periodic review by the Company, and a bonus opportunity that
has a target payout of 50% of his base salary. For our fiscal year ended June 30, 2021, Mr. Finio&rsquo;s bonus will be pro-rated
based on his start date. In addition, Mr. Finio will receive a signing bonus in the gross amount of $150,000, which will be paid
in two equal payments, with the first $75,000 paid within thirty (30) days of the commencement of his employment and the second
$75,000 paid six months from the commencement of his employment, provided in each case Mr. Finio is still employed by the Company
on the applicable payment date. Mr. Finio will be bound by customary confidentiality, noncompete, nonsolicitation, and intellectual
property provisions, which generally apply during employment and thereafter (with the noncompete and nonsolicitation provisions
applying during employment and the one-year period thereafter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>(d) Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 10%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Number</B></P></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 88%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Description</B></P></TD></TR>
<TR>
    <TD STYLE="border-top: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A HREF="tm2030959d1_ex99-1.htm" STYLE="-sec-extract: exhibit">99.1</A></P></TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A HREF="tm2030959d1_ex99-1.htm" STYLE="-sec-extract: exhibit">Press Release, dated September 17, 2020.</A></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="vertical-align: top; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PHIBRO ANIMAL HEALTH CORPORATION</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Registrant</P></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: September 17, 2020</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 50%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 5%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 45%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Thomas G. Dagger</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;<BR>
Title:</FONT></TD>
    <TD STYLE="border-top: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas G. Dagger<BR>
Senior Vice President, General Counsel <BR>
and Corporate Secretary</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2030959d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<IMG SRC="image_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For Immediate Release</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Phibro Animal Health Corporation Announces
Chief Financial Officer Changes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>TEANECK, N.J., September 17, 2020 (Business Wire)</B> -
Phibro Animal Health Corporation (the &ldquo;Company&rdquo; or &ldquo;Phibro&rdquo;) today announced that Richard Johnson, Phibro&rsquo;s
Chief Financial Officer, has informed the Company that he will retire from his position effective November 15, 2020, subsequent
to the Company&rsquo;s annual meeting and completion of the Company&rsquo;s earnings report for the quarter ending September 30,
2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Phibro also announced that Damian Finio will join Phibro on
October 26, 2020, and will succeed Mr. Johnson as Phibro&rsquo;s Chief Financial Officer, effective November 15, 2020. Mr. Johnson
will continue with Phibro for a period of time in an advisory capacity to ensure a smooth transition with his successor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;I want to take this opportunity to recognize and thank
Dick for his many contributions to the success of Phibro over the past 18 years, and to wish him all the best in his retirement,&rdquo;
said Jack Bendheim, Phibro&rsquo;s Chairman, President and Chief Executive Officer. &ldquo;I also want to welcome Damian to Phibro.
He brings the skills and experience needed to play a key role in Phibro&rsquo;s future development.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Since February 2018, Mr. Finio, age 50, has served as Chief
Financial Officer of Teligent, Inc. a publicly traded global manufacturer and distributor of topical pharmaceutical products in
the United States and injectable pharmaceutical products in Canada. Mr. Finio has over 29 years of financial management experience.
From November 2015 through January 2018, Mr. Finio served as Chief Financial Officer of Virtus Pharmaceuticals LLC. Prior to this,
Mr. Finio served in a variety of financial roles of increasing responsibility at Daiichi Sankyo Pharma Development, West-Ward Pharmaceuticals
(now known as Hikma), and Heritage Pharmaceuticals Inc. (now known as Avet Pharmaceuticals Inc.), after spending nearly fourteen
years with AstraZeneca. He began his career in public accounting at KPMG LLP. Mr. Finio has a Bachelor of Science in Accounting
from The Pennsylvania State University and a Masters in Business Administration from the University of Delaware, and is an (inactive)
Certified Public Accountant and (inactive) Certified Treasury Professional.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Phibro Animal Health Corporation </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Phibro Animal Health Corporation is a diversified global developer,
manufacturer and supplier of a broad range of animal health and mineral nutrition products for livestock, helping veterinarians
and farmers produce healthy, affordable food while using fewer natural resources. For further information, please visit <U>www.pahc.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Contacts</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Phibro Animal Health Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Richard Johnson</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">+1-201-329-7300</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">investor.relations@pahc.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  Z +,# 2(  A$! Q$!_\0
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8'V*VP, ?NEX '':BO;7L;?#^)M[W<__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
